The global perfusion systems market size was valued at USD 1.07 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2030. Factors such as increase in prevalence of cardiovascular and respiratory diseases, rise in number of organ transplantation, growth in geriatric population and multiple organ failures are expected to drive the growth of the market.Other factors such as increasing investment in cell-based research, government and NGO initiatives to encourage organ donation and rise in biologic manufacturing are also expected to boost the market growth over the forecast period. The COVID-19 pandemic that affected almost every country around the world and led to a major loss of life had a slightly negative impact on the market. While the cardiac surgeries were still carried out due to the chronic nature and the life-threatening risk that it possesses, there was a significant drop in number of organ donations and transplants during the pandemic due to the lockdowns and restrictions imposed by the government. Thus, the market experienced significant fall in sales of perfusion system during the pandemic.
Moreover, the lockdowns and restrictions led by the government disrupted the manufacturing processes as well as the overall supply chain. It also resulted in disruption of research and development activities which may have resulted in postponement of launch of new products in the market. In addition, reduced patient visits to the hospital as a precautionary measure to avoid contracting the virus also had a significant negative impact on the market.
However, with the world now returning to normalcy and the countries majorly focusing on healthcare, the perfusion system market is expected to continue generating significant amount of revenue during the forecast period. With launch of new products, the market is expected to experience pre-covid growth rate over the forecast period.
Rise in prevalence of cardiac and respiratory diseases is majorly contributing towards the growth of perfusion system market. Factors such as increasing consumption of processed foods, reduced physical activities and increase in overall lifespan of individuals, which has resulted in increase in number of geriatric population is leading to a rise in prevalence of cardiac and respiratory diseases. According to the CDC’s 2022 data, in the U.S., every year about 805,000 people have a heart attack and out of this 605,000 people are those who get it for the first time.
Rise in number of organ transplants is another factor that is expected to boost the market growth to a great extent over the forecast period. According to the preliminary data of United Network of Organ Sharing, in 2021, the U.S. observed a 5.9 percent rise in organ transplants from 2020. The data also stated that, in 2021, around 13,861 Americans became deceased organ donors.
The cardiopulmonary perfusion system held the highest share of more than 44.30% in 2022 owing to the increasing prevalence of cardiovascular & respiratory diseases and a rapid rise in the number of organ transplant procedures being carried across the globe.
The Ex-vivo organ perfusion system is getting popularity in the recent years. This is because the ex-vivo perfusion system has the capability to allow organs to survive longer outside the body and make immediate transplant less urgent. This further helps the number of organs available for transplant to grow.
The cardiopulmonary perfusion system is further classified into oxygenators, heart-lung machine, perfusion pumps, cannula, monitoring system and others. The oxygenator segment held the largest share in 2022 owing to the rising incidence of cardiopulmonary failure.
The cell perfusion system is further segmented into bioreactor perfusion system, microfluidic perfusion system, gravity/pressure-driven perfusion system and small mammal organ perfusion system. The bioreactor perfusion system dominated the cell perfusion system segment with highest share in 2022. This is attributed towards factors such as, rising demand for biological products and constant need to increase product yield & reduce production costs.
The Ex-vivo organ perfusion system is further segmented into hypothermic and normothermic. The hypothermic segment accounted for highest market share in 2022. This can be attributed towards the advantages that hypothermic perfusion system offers such as, better long-term graft survival rates, ability to provide metabolic support and decreased vasospasm.
North America dominated the perfusion system market with the highest market share of 39.64% in 2022. This is attributed towards enormous healthcare spending and advantageous health cover policies by both government and private insurers. Growing number of organ donors is a major factor contributing towards the growth of perfusion system in this region. According to the Health Resources & Services Administration, in U.S., more than 40,000 transplants were carried out in 2021.
However, Asia Pacific region is projected to undergo maximum growth during the forecast period. Factors such as increase in geriatric population, shift towards sedentary lifestyle which is contributing towards a rise in the prevalence of chronic diseases are driving the growth of the market in this region. Various government initiatives in this region is also anticipated to boost the growth of perfusion systems market. Moreover, countries like India and China, where the number of patients in need of organ transplant is way higher than the number of organ donors, which is a cause of concern for the government and healthcare officials and therefore these countries are focusing on developing various strategies to promote organ donation.
Key players manufacturing perfusion systems are focusing on various strategic initiatives to boost their market presence and overall position in the market. Launch of new products, strategic acquisitions and mergers and partnerships are some of the initiatives carried out by the key players to strengthen their position in the market. For instance, in April 2022, LivaNova announced the commercial launch of Essenz patient monitor. The monitor uses a patient-tailored approach to improve efficiency and quality of care during cardiopulmonary bypass (CPB) procedures. Some of the prominent key players operating in the perfusion systems market include:
Getinge AB
Medtronic, plc
LivaNova
Terumo Corporation
Nipro Corporation
XENIOS AG
Repligen Corporation
Spectrum Laboratories, Inc.
Merck KGaA
Harvard Bioscience, Inc.
ALA Scientific Instruments, Inc.
Lifeline Scientific, Inc.
XVIVO Perfusion AB
Report Attribute |
Details |
Market size value in 2023 |
USD 1.1 billion |
Revenue forecast in 2030 |
USD 1.5 billion |
Growth rate |
CAGR of 4.7% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
June 2023 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; China; Japan; India; Australia; South Korea; Singapore; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE |
Key companies profiled |
Getinge AB; Medtronic, plc; LivaNova; Terumo Corporation; Nipro Corporation; XENIOS AG; Repligen Corporation; Spectrum Laboratories, Inc.; Merck KGaA; Harvard Bioscience, Inc.; ALA Scientific Instruments, Inc.; Lifeline Scientific, Inc.; XVIVO Perfusion AB |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global perfusion systems market report on the basis of application, and region:
Application Outlook (Revenue in USD Million; 2018 - 2030)
Cardiopulmonary Perfusion System
Oxygenators
Heart-Lung Machine
Perfusion Pumps
Cannula
Monitoring System
Others
Cell Perfusion System
Bioreactor Perfusion System
Microfluidic Perfusion System
Gravity/Pressure-driven Perfusion System
Small Mammal Organ Perfusion System
Ex-Vivo Organ Perfusion System
Hypothermic
Normothermic
Regional Outlook (Revenue in USD Million; 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Russia
Asia Pacific
China
Japan
India
Australia
South Korea
Singapore
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
b. Key factors that are driving the market growth include increasing demand for organ transplantation, technological advancements and increasing initiatives to promote organ donation.
b. The global perfusion systems market size was estimated at USD 1.07 billion in 2022 and is expected to reach USD 1.1 billion in 2023.
b. The global perfusion systems market is expected to grow at a compound annual growth rate of 4.7% from 2023 to 2030 to reach USD 1.5 billion by 2030.
b. North America dominated the perfusion systems market with a share of 39.6% in 2022. This is attributable to the increasing demand for transplant surgery and initiatives undertaken by the government.
b. Some key players operating in the perfusion systems market include XVIVO Perfusion AB; Organ Assist B.V.; Organ Recovery Systems; Organ Transport Systems; Waters Medical Systems; Paragonix Technologies, Inc.; TransMedics, Inc.; OrganOx Limited; and Bridge to Life Ltd.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.